IL269286B2 - Subcutaneous administration of a p2y12 receptor antagonist - Google Patents
Subcutaneous administration of a p2y12 receptor antagonistInfo
- Publication number
- IL269286B2 IL269286B2 IL269286A IL26928619A IL269286B2 IL 269286 B2 IL269286 B2 IL 269286B2 IL 269286 A IL269286 A IL 269286A IL 26928619 A IL26928619 A IL 26928619A IL 269286 B2 IL269286 B2 IL 269286B2
- Authority
- IL
- Israel
- Prior art keywords
- receptor antagonist
- administered
- pharmaceutically acceptable
- acceptable salt
- use according
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Dermatology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP2017056175 | 2017-03-15 | ||
| PCT/EP2018/056372 WO2018167139A1 (en) | 2017-03-15 | 2018-03-14 | Subcutaneous administration of a p2y12 receptor antagonist |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| IL269286A IL269286A (en) | 2019-11-28 |
| IL269286B1 IL269286B1 (en) | 2023-04-01 |
| IL269286B2 true IL269286B2 (en) | 2023-08-01 |
Family
ID=61899166
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL269286A IL269286B2 (en) | 2017-03-15 | 2019-09-11 | Subcutaneous administration of a p2y12 receptor antagonist |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US11179390B2 (enExample) |
| EP (1) | EP3595666A1 (enExample) |
| JP (3) | JP7580918B2 (enExample) |
| KR (1) | KR102510832B1 (enExample) |
| CN (1) | CN110381947A (enExample) |
| AU (1) | AU2018234056B2 (enExample) |
| BR (1) | BR112019014567A2 (enExample) |
| CA (1) | CA3050831A1 (enExample) |
| CL (1) | CL2019002318A1 (enExample) |
| EA (1) | EA201992123A1 (enExample) |
| IL (1) | IL269286B2 (enExample) |
| MA (1) | MA49887A (enExample) |
| MX (1) | MX393334B (enExample) |
| MY (1) | MY205605A (enExample) |
| PH (1) | PH12019502111A1 (enExample) |
| SG (1) | SG11201908128YA (enExample) |
| TW (1) | TWI765002B (enExample) |
| UA (1) | UA125531C2 (enExample) |
| WO (1) | WO2018167139A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX381590B (es) | 2016-09-22 | 2025-03-12 | Idorsia Pharmaceuticals Ltd | Una forma cristalina de clorhidrato de éster butílico del ácido 4-((r)-2-{[6-((s)-3-metoxi-pirrolidina-1-il)-2-fenil-pirimidina-4-carbonil]-amino}-3-fosfonopropionil)-piperazin-1-carboxílico. |
| KR20230041732A (ko) | 2020-07-15 | 2023-03-24 | 이도르시아 파마슈티컬스 리미티드 | P2y12 수용체 안타고니스트를 포함하는 수성 약제학적 조성물 |
| KR20240033005A (ko) | 2021-07-13 | 2024-03-12 | 이도르시아 파마슈티컬스 리미티드 | 4-((r)-2-｛[6-((s)-3-메톡시-피롤리딘-1-일)-2-페닐-피리미딘-4-카르보닐]-아미노｝-3-포스포노-프로피오닐)-피페라진-1-카르복실산부틸 에스테르의 합성 방법 |
| WO2023174810A1 (en) | 2022-03-14 | 2023-09-21 | Idorsia Pharmaceuticals Ltd | A process for the synthesis of ( r)-2-(( tert-butoxycarbonyl)amino)-3-(diethoxyphosphoryl)propanoic acid or of phosphonate derivatives thereof |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3870035A (en) | 1970-07-17 | 1975-03-11 | Survival Technology | Method and apparatus for self-administering pre-hospital phase treatment of coronary prone individuals in the early minutes or hours after the onset of heart attack symptoms |
| US4004577A (en) | 1972-12-04 | 1977-01-25 | Survival Technology, Inc. | Method of treating heart attack patients prior to the establishment of qualified direct contact personal care |
| JPS5373586A (en) | 1976-12-09 | 1978-06-30 | Mitsubishi Chem Ind Ltd | New penicillin derivatives |
| US5078680A (en) | 1984-08-08 | 1992-01-07 | Survival Technology, Inc. | Automatic injector for emergency treatment |
| US4795433A (en) | 1985-05-20 | 1989-01-03 | Survival Technology, Inc. | Automatic injector for emergency treatment |
| US4658830A (en) | 1984-08-08 | 1987-04-21 | Survival Technology, Inc. | Method and apparatus for initiating reperfusion treatment by an unattended individual undergoing heart attack symptoms |
| GR861289B (en) | 1985-05-20 | 1986-09-16 | Survival Technology | Injection method and apparatus with electrical blood absorbing stimulation |
| CA2020437A1 (en) | 1989-07-05 | 1991-01-06 | Yoshihide Fuse | Cinnamamide derivative |
| JP2003502314A (ja) | 1999-06-14 | 2003-01-21 | イーライ・リリー・アンド・カンパニー | 化合物 |
| US6861424B2 (en) | 2001-06-06 | 2005-03-01 | Schering Aktiengesellschaft | Platelet adenosine diphosphate receptor antagonists |
| MXPA05006302A (es) | 2002-12-11 | 2005-08-29 | Schering Ag | Compuestos de 2-aminocarbonilquinolina como antagonistas de receptor de difosfato de adenosina plaquetario. |
| MXPA05010760A (es) | 2003-04-09 | 2005-12-12 | Wyeth Corp | Derivados de acido 2-(8,9-dioxo-2,6-diazabiciclo[5.2.0]non-1(7)-en-2-il)alquil fosfonico y su uso como antagonistas de receptor de n-metil-d-aspartato (nmda). |
| AU2003249865A1 (en) | 2003-06-24 | 2005-01-21 | Actelion Pharmaceuticals Ltd | Pyrazolidinedione derivatives and their use as platelet aggregation inhibitors |
| TW200640877A (en) | 2005-04-28 | 2006-12-01 | Actelion Pharmaceuticals Ltd | Pyrimidine derivatives |
| MY147373A (en) | 2005-10-21 | 2012-11-30 | Actelion Pharmaceuticals Ltd | Piperazine derivatives as antimalarial agents |
| AR063258A1 (es) | 2006-10-13 | 2009-01-14 | Actelion Pharmaceuticals Ltd | Derivados de 2-aminocarbonil-piridina, una composicion farmaceutica que los contiene y su uso en la preparacion de un medicamento para el tratamiento de trastornos vasculares oclusivos. |
| CL2007003038A1 (es) | 2006-10-25 | 2008-06-06 | Actelion Pharmaceuticals Ltd | Compuestos derivados de 2-fenil-6-aminocarbonil-pirimidina; composicion farmaceutica; y uso en el tratamiento de trastornos vasculares oclusivos. |
| JP4785881B2 (ja) | 2007-02-27 | 2011-10-05 | 大塚製薬株式会社 | 医薬 |
| AU2008241091B2 (en) | 2007-04-23 | 2013-05-09 | Sanofi-Aventis | Quinoline-carboxamide derivatives as P2Y12 antagonists |
| BRPI0811476A2 (pt) | 2007-05-02 | 2014-11-04 | Portola Pharm Inc | Dosagem intravenosa e oral de um inibidor de p2y12 de ação direta e reversível |
| AU2008331163B2 (en) | 2007-11-29 | 2014-01-30 | Viatris Asia Pacific Pte. Ltd. | Phosphonic acid derivates and their use as P2Y12 receptor antagonists |
| EP2238127B1 (en) | 2007-12-26 | 2012-08-15 | Sanofi | Pyrazole-carboxamide derivatives as p2y12 antagonists |
| EP2238128B1 (en) | 2007-12-26 | 2012-08-22 | Sanofi | Heterocyclic pyrazole-carboxamides as p2y12 antagonists |
| AR071652A1 (es) | 2008-04-11 | 2010-07-07 | Actelion Pharmaceuticals Ltd | Derivados 2- fenil-piridina substituidos |
| AR071653A1 (es) | 2008-04-11 | 2010-07-07 | Actelion Pharmaceuticals Ltd | Derivados 2-fenil-4-ciclopropil-pirimidina |
| JP5536873B2 (ja) | 2009-04-08 | 2014-07-02 | アクテリオン ファーマシューティカルズ リミテッド | ６−（３−アザ−ビシクロ［３．１．０］ヘクス−３−イル）−２−フェニル−ピリミジン（６−（３−ａｚａ−ｂｉｃｙｃｌｏ［３．１．０］ｈｅｘ−３−ｙｌ）−２−ｐｈｅｎｙｌ−ｐｙｒｉｍｉｄｉｎｅｓ） |
| CN102405220B (zh) | 2009-04-22 | 2015-05-27 | 埃科特莱茵药品有限公司 | 噻唑衍生物及其作为p2y12受体拮抗剂的用途 |
| WO2011137459A1 (en) | 2010-04-30 | 2011-11-03 | Portola Pharmaceuticals, Inc. | Dosage forms of elinogrel and methods of injectable administration thereof |
| WO2011160768A1 (en) | 2010-06-23 | 2011-12-29 | Stefan Kralev | Medical device for self-administration of patients with acute coronary events |
| MX381590B (es) | 2016-09-22 | 2025-03-12 | Idorsia Pharmaceuticals Ltd | Una forma cristalina de clorhidrato de éster butílico del ácido 4-((r)-2-{[6-((s)-3-metoxi-pirrolidina-1-il)-2-fenil-pirimidina-4-carbonil]-amino}-3-fosfonopropionil)-piperazin-1-carboxílico. |
-
2018
- 2018-03-14 US US16/494,254 patent/US11179390B2/en active Active
- 2018-03-14 SG SG11201908128Y patent/SG11201908128YA/en unknown
- 2018-03-14 CN CN201880017104.XA patent/CN110381947A/zh active Pending
- 2018-03-14 EP EP18715499.2A patent/EP3595666A1/en active Pending
- 2018-03-14 BR BR112019014567-2A patent/BR112019014567A2/pt not_active Application Discontinuation
- 2018-03-14 CA CA3050831A patent/CA3050831A1/en active Pending
- 2018-03-14 KR KR1020197029753A patent/KR102510832B1/ko active Active
- 2018-03-14 EA EA201992123A patent/EA201992123A1/ru unknown
- 2018-03-14 MX MX2019009559A patent/MX393334B/es unknown
- 2018-03-14 WO PCT/EP2018/056372 patent/WO2018167139A1/en not_active Ceased
- 2018-03-14 MA MA049887A patent/MA49887A/fr unknown
- 2018-03-14 AU AU2018234056A patent/AU2018234056B2/en active Active
- 2018-03-14 MY MYPI2019005278A patent/MY205605A/en unknown
- 2018-03-14 UA UAA201910293A patent/UA125531C2/uk unknown
- 2018-03-14 JP JP2019549420A patent/JP7580918B2/ja active Active
- 2018-03-14 TW TW107108546A patent/TWI765002B/zh active
-
2019
- 2019-08-16 CL CL2019002318A patent/CL2019002318A1/es unknown
- 2019-09-11 IL IL269286A patent/IL269286B2/en unknown
- 2019-09-13 PH PH12019502111A patent/PH12019502111A1/en unknown
-
2023
- 2023-01-23 JP JP2023008155A patent/JP2023052576A/ja active Pending
-
2024
- 2024-12-26 JP JP2024230902A patent/JP2025060907A/ja active Pending
Non-Patent Citations (3)
| Title |
|---|
| BALDONI DANIELA ET AL,, A NEW REVERSIBLE AND POTENT P2Y12 RECEPTOR ANTAGONIST (ACT-246475): TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS IN A FIRST-IN-MAN TRIAL, 1 November 2014 (2014-11-01) * |
| EVA CAROFF ET AL,, 4-(( R )-2-{[6-(( S )-3-METHOXYPYRROLIDIN-1-YL)-2-PHENYLPYRIMIDINE-4-CARBONYL]AMINO}-3-PHOSPHONOPROPIONYL)PIPERAZINE-1-CARBOXYLIC ACID BUTYL ESTER (ACT-246475) AND ITS PRODRUG (ACT-281959), A NOVEL P2Y 12 RECEPTOR ANTAGONIST WITH A WIDER THERAPEUTIC , 10 December 2015 (2015-12-10) * |
| PEER TFELT-HANSEN,, PARENTERAL VS. ORAL SUMATRIPTAN AND NARATRIPTAN: PLASMA LEVELS AND EFFICACY IN MIGRAINE. A COMMENT, 23 January 2007 (2007-01-23) * |
Also Published As
| Publication number | Publication date |
|---|---|
| IL269286A (en) | 2019-11-28 |
| AU2018234056B2 (en) | 2023-05-25 |
| JP2023052576A (ja) | 2023-04-11 |
| CA3050831A1 (en) | 2018-09-20 |
| MY205605A (en) | 2024-10-29 |
| JP7580918B2 (ja) | 2024-11-12 |
| US11179390B2 (en) | 2021-11-23 |
| US20200129510A1 (en) | 2020-04-30 |
| AU2018234056A1 (en) | 2019-10-31 |
| BR112019014567A2 (pt) | 2020-02-18 |
| JP2020510043A (ja) | 2020-04-02 |
| KR102510832B1 (ko) | 2023-03-15 |
| EA201992123A1 (ru) | 2020-02-25 |
| NZ757938A (en) | 2024-07-05 |
| MA49887A (fr) | 2020-06-24 |
| TW201840323A (zh) | 2018-11-16 |
| IL269286B1 (en) | 2023-04-01 |
| CL2019002318A1 (es) | 2020-01-10 |
| MX2019009559A (es) | 2019-10-15 |
| PH12019502111A1 (en) | 2020-03-16 |
| TWI765002B (zh) | 2022-05-21 |
| EP3595666A1 (en) | 2020-01-22 |
| SG11201908128YA (en) | 2019-10-30 |
| KR20190124297A (ko) | 2019-11-04 |
| CN110381947A (zh) | 2019-10-25 |
| UA125531C2 (uk) | 2022-04-13 |
| WO2018167139A1 (en) | 2018-09-20 |
| JP2025060907A (ja) | 2025-04-10 |
| MX393334B (es) | 2025-03-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2025060907A (ja) | Ｐ２ｙ１２受容体アンタゴニストの皮下投与 | |
| EP3380095B1 (en) | Compositions and methods for treating ischemic stroke | |
| KR20180032578A (ko) | 염증 및 암 질환의 치료를 위한 클로로퀸 및 클레미졸 화합물의 용도 | |
| CA2677931A1 (en) | Use of ranolazine for the treatment of cardiovascular diseases | |
| KR20140022052A (ko) | 심근 경색 후 환자에서의 심부전 및 부정맥 치료를 위한 ａ２ｂ 아데노신 수용체 안타고니스트의 용도 | |
| KR20110013352A (ko) | 심혈관 질환을 치료하기 위한 라놀라진의 용도 | |
| KR20100038322A (ko) | 당뇨병 치료 방법 | |
| EP4592294A1 (en) | Novel carbamate compound and use thereof | |
| EP4181872B1 (en) | Aqueous pharmaceutical composition comprising a p2y12 receptor antagonist | |
| JP2023082167A (ja) | 薬物動態及び／又は安全性に優れるテリパラチド含有液状医薬組成物 | |
| EA042138B1 (ru) | Подкожное введение антагониста p2y12 рецептора | |
| TWI905227B (zh) | 包含p2y12受體拮抗劑的水性醫藥組合物 | |
| Thakur¹ et al. | Review on chemistry and pharmacology of dabigatran a potent anticoagulant |